BRAF and melanoma: Combination therapy in adults with BRAF mutated melanoma has yielded higher objective response rates, prolonged survival rates, decreased rates of resistance, and decreased incidence of side effects most notably skin toxicities when compared to BRAF inhibitor monotherapy [9, 10, 15].